By On July 17th, 2015

Monoclonal antibodies may prevent CTE

iStock_000001017387MediumKun Ping Lu, MD, PhD and his research team at Beth Israel Deaconess Medical Center and Harvard Medical school have connected the development of CTE with high levels of cis P-tau, a protein associated with the plaques seen in CTE (Chronic Traumatic Encephalopathy). The build-up is seen as early as 12 hours to 2 months after the injury and spreading from the cortex to the hypothalmus over time. The research team found that a monoclonal anti-body was effective to reducing cis P-tau levels in the mouse study they conducted. If the monoclonal antibody therapy can prevent cis P-tau in humans it may go a long way to dealing with neurodegenerative problems associated with brain injury like CTE and Alzheimers Disease.

Click here to read the MedPage story about this research.


Leave a Reply

You must be logged in to post a comment.

Logo Logo Logo

©2024 Neurologic Rehabilitation Institute. All Rights Reserved.